Braindead
09-09-2007, 02:04 AM
I switched from Lipitor to Zocor (simvastatin) 20 mg about two years ago because I came across some comments saying that Zocor might have some neurological advantages. (It is now Generic ). It is more a preventative thing for high risk and may not be an effective treatment. That needs some more real research!
This seems to support my opinion and my decision to change to Zocor.
"In patients over age 64, those who took Zocor were 54% less likely to get Alzheimer's disease and 49% less likely to get Parkinson's disease than were matched patients not taking statin drugs.
Those who took Lipitor were 9% less likely to get Alzheimer's disease, a finding that was not statistically significant. Lipitor did not affect Parkinson's disease risk.
Mevacor had no effect on risk of either Alzheimer's disease or Parkinson's disease."
Comments welcomed and requested.
Braindead
p.s My LDL is 72 and my HDL is 74. No loss in cholesterol control with Zocor.
1: BMC Med. 2007 Jul 19;5:20.
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE.
Boston University School of Medicine, Boston, MA, USA.
BACKGROUND: Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease.
METHODS: We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease.
RESULTS: We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001).
CONCLUSION: Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance.
PMID: 17640385 [PubMed - in process]
http://www.biomedcentral.com/1741-7015/5/20 ( more complete presentation )
Zocor vs. Alzheimer's and Parkinson's
Cholesterol Drug Zocor May Lower Risk of Both Alzheimer's, Parkinson's Diseases
By Daniel J. DeNoon
WebMD Medical News
Reviewed by Louise Chang, MD
July 18, 2007 -- Zocor -- but not sister cholesterol-lowering drugs Lipitor or Mevacor -- may cut the risk of both Alzheimer's and Parkinson's disease, a new study suggests.
It's not the first time that the cholesterol-lowering drugs known as statins have been linked to Alzheimer's disease. A small clinical trial in 2005 suggested that Lipitor might improve mental function in people with early Alzheimer's disease.
Both Lipitor and Zocor are in clinical trials to see whether they really do help people with Alzheimer's disease. But now there's compelling evidence that Zocor may actually prevent not only Alzheimer's disease, but Parkinson's disease, too.
The provocative new data come from Boston University researcher Benjamin Wolozin, MD, and colleagues.
"Many people are looking at whether statins might prevent the progression of dementia in people with Alzheimer's disease," Wolozin tells WebMD. "But a lot of people in the field think that if you start statin treatment at the time you already have the disease, it might be the wrong time. It might be nice to talk about how to prevent the disease."
To see whether taking statins had any effect on Alzheimer's disease, Wolozin's team used the immense U.S. Veterans Affairs database, with detailed information on 4.5 million patients. Some 727,000 of these patients took Zocor, about 54,000 took Lipitor, and about 54,000 took Mevacor.
In patients over age 64, those who took Zocor were 54% less likely to get Alzheimer's disease and 49% less likely to get Parkinson's disease than were matched patients not taking statin drugs.
Those who took Lipitor were 9% less likely to get Alzheimer's disease, a finding that was not statistically significant. Lipitor did not affect Parkinson's disease risk.
Mevacor had no effect on risk of either Alzheimer's disease or Parkinson's disease.
D. Larry Sparks, PhD, director of the Roberts Laboratory for Neurodegenerative Disease Research at the Sun Health Research Institute in Sun City, Ariz., is involved in clinical trials of statins for Alzheimer's disease but was not involved in the Wolozin study.
"This study keeps alive the idea that statins may be of benefit in the treatment of Alzheimer's disease and maybe even in mild cognitive impairment," Sparks tells WebMD. "But the most important part is that this addresses the role of cholesterol-lowering medications as a way to combat Parkinson's disease."
The study does not offer answers to the question of why Zocor seems to work better than Lipitor in preventing Alzheimer's and Parkinson's diseases.
Is it time to start taking Zocor to prevent neurodegenerative diseases? Wolozin says people should take statins only to lower high cholesterol levels.
"If your parents got Alzheimer's disease and you have high cholesterol, you might want to talk with your doctor about whether you should take Zocor or Lipitor," Wolozin says. "If your parents don't have Alzheimer's disease, but, say, your dad had a heart attack, you should probably take Lipitor, because it is somewhat better at preventing some of the [problems ] associated with heart disease. You have to look at your own personal risk factors."
Proof of whether statins affect risk of Alzheimer's disease or Parkinson's disease can come only from controlled clinical trials. But as such trials would be extremely lengthy and expensive, Wolozin doubts they will be undertaken.
Help may come from ongoing trials looking at whether Lipitor or Zocor can help people who already have Alzheimer's disease. Those trials are nearly over; results are expected next year.
The Wolozin study appears in the July issue of the online journal BioMed Central Medicine.
This seems to support my opinion and my decision to change to Zocor.
"In patients over age 64, those who took Zocor were 54% less likely to get Alzheimer's disease and 49% less likely to get Parkinson's disease than were matched patients not taking statin drugs.
Those who took Lipitor were 9% less likely to get Alzheimer's disease, a finding that was not statistically significant. Lipitor did not affect Parkinson's disease risk.
Mevacor had no effect on risk of either Alzheimer's disease or Parkinson's disease."
Comments welcomed and requested.
Braindead
p.s My LDL is 72 and my HDL is 74. No loss in cholesterol control with Zocor.
1: BMC Med. 2007 Jul 19;5:20.
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE.
Boston University School of Medicine, Boston, MA, USA.
BACKGROUND: Statins are a class of medications that reduce cholesterol by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Whether statins can benefit patients with dementia remains unclear because of conflicting results. We hypothesized that some of the confusion in the literature might arise from differences in efficacy of different statins. We used a large database to compare the action of several different statins to investigate whether some statins might be differentially associated with a reduction in the incidence of dementia and Parkinson's disease.
METHODS: We analyzed data from the decision support system of the US Veterans Affairs database, which contains diagnostic, medication and demographic information on 4.5 million subjects. The association of lovastatin, simvastatin and atorvastatin with dementia was examined with Cox proportional hazard models for subjects taking statins compared with subjects taking cardiovascular medications other than statins, after adjusting for covariates associated with dementia or Parkinson's disease.
RESULTS: We observed that simvastatin is associated with a significant reduction in the incidence of dementia in subjects > or =65 years, using any of three models. The first model incorporated adjustment for age, the second model included adjusted for three known risk factors for dementia, hypertension, cardiovascular disease or diabetes, and the third model incorporated adjustment for the Charlson index, which is an index that provides a broad assessment of chronic disease. Data were obtained for over 700,000 subjects taking simvastatin and over 50,000 subjects taking atorvastatin who were aged >64 years. Using model 3, the hazard ratio for incident dementia for simvastatin and atorvastatin are 0.46 (CI 0.44-0.48, p < 0.0001) and 0.91 (CI 0.80-1.02, p = 0.11), respectively. Lovastatin was not associated with a reduction in the incidence of dementia. Simvastatin also exhibited a reduced hazard ratio for newly acquired Parkinson's disease (HR 0.51, CI 0.4-0.55, p < 0.0001).
CONCLUSION: Simvastatin is associated with a strong reduction in the incidence of dementia and Parkinson's disease, whereas atorvastatin is associated with a modest reduction in incident dementia and Parkinson's disease, which shows only a trend towards significance.
PMID: 17640385 [PubMed - in process]
http://www.biomedcentral.com/1741-7015/5/20 ( more complete presentation )
Zocor vs. Alzheimer's and Parkinson's
Cholesterol Drug Zocor May Lower Risk of Both Alzheimer's, Parkinson's Diseases
By Daniel J. DeNoon
WebMD Medical News
Reviewed by Louise Chang, MD
July 18, 2007 -- Zocor -- but not sister cholesterol-lowering drugs Lipitor or Mevacor -- may cut the risk of both Alzheimer's and Parkinson's disease, a new study suggests.
It's not the first time that the cholesterol-lowering drugs known as statins have been linked to Alzheimer's disease. A small clinical trial in 2005 suggested that Lipitor might improve mental function in people with early Alzheimer's disease.
Both Lipitor and Zocor are in clinical trials to see whether they really do help people with Alzheimer's disease. But now there's compelling evidence that Zocor may actually prevent not only Alzheimer's disease, but Parkinson's disease, too.
The provocative new data come from Boston University researcher Benjamin Wolozin, MD, and colleagues.
"Many people are looking at whether statins might prevent the progression of dementia in people with Alzheimer's disease," Wolozin tells WebMD. "But a lot of people in the field think that if you start statin treatment at the time you already have the disease, it might be the wrong time. It might be nice to talk about how to prevent the disease."
To see whether taking statins had any effect on Alzheimer's disease, Wolozin's team used the immense U.S. Veterans Affairs database, with detailed information on 4.5 million patients. Some 727,000 of these patients took Zocor, about 54,000 took Lipitor, and about 54,000 took Mevacor.
In patients over age 64, those who took Zocor were 54% less likely to get Alzheimer's disease and 49% less likely to get Parkinson's disease than were matched patients not taking statin drugs.
Those who took Lipitor were 9% less likely to get Alzheimer's disease, a finding that was not statistically significant. Lipitor did not affect Parkinson's disease risk.
Mevacor had no effect on risk of either Alzheimer's disease or Parkinson's disease.
D. Larry Sparks, PhD, director of the Roberts Laboratory for Neurodegenerative Disease Research at the Sun Health Research Institute in Sun City, Ariz., is involved in clinical trials of statins for Alzheimer's disease but was not involved in the Wolozin study.
"This study keeps alive the idea that statins may be of benefit in the treatment of Alzheimer's disease and maybe even in mild cognitive impairment," Sparks tells WebMD. "But the most important part is that this addresses the role of cholesterol-lowering medications as a way to combat Parkinson's disease."
The study does not offer answers to the question of why Zocor seems to work better than Lipitor in preventing Alzheimer's and Parkinson's diseases.
Is it time to start taking Zocor to prevent neurodegenerative diseases? Wolozin says people should take statins only to lower high cholesterol levels.
"If your parents got Alzheimer's disease and you have high cholesterol, you might want to talk with your doctor about whether you should take Zocor or Lipitor," Wolozin says. "If your parents don't have Alzheimer's disease, but, say, your dad had a heart attack, you should probably take Lipitor, because it is somewhat better at preventing some of the [problems ] associated with heart disease. You have to look at your own personal risk factors."
Proof of whether statins affect risk of Alzheimer's disease or Parkinson's disease can come only from controlled clinical trials. But as such trials would be extremely lengthy and expensive, Wolozin doubts they will be undertaken.
Help may come from ongoing trials looking at whether Lipitor or Zocor can help people who already have Alzheimer's disease. Those trials are nearly over; results are expected next year.
The Wolozin study appears in the July issue of the online journal BioMed Central Medicine.